Digoxin In NASH (CODIN)
NCT06588699
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
Nonalcoholic steatohepatitis (NASH) is a severe subtype of nonalcoholic fatty liver disease (NAFLD) which affects 1 in 3 Americans. The mainstay of treatment for NASH, which was recently renamed metabolic associated steatohepatitis (MASH), involves lifestyle interventions to promote weight loss and to treat comorbidities such as hypertension, hyperlipidemia, and diabetes mellitus.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- NASH
- NAFLD
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Mash
- MASH With Fibrosis
- MASLD
- Fatty Liver Disease
- Fatty Liver Disease, Nonalcoholic
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 75 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Yale University
- Last updated on ClinicalTrials.gov
- May 26, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Connecticut · 2
- Yale New Haven Health · New Haven, CT
- Yale New Haven Hospital · New Haven, CT
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.